Quintiles Transitional Holdings Inc. (NYSE:Q) Director John Connaughton sold 1,030,429 shares of the business’s stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $94.87, for a total transaction of $97,756,799.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Quintiles Transitional Holdings Inc. (Q) traded down 0.44% on Thursday, hitting $94.22. 921,266 shares of the stock were exchanged. The company’s 50-day moving average is $93.80 and its 200-day moving average is $86.86. Quintiles Transitional Holdings Inc. has a 52 week low of $70.10 and a 52 week high of $99.95. The company has a market cap of $20.40 billion, a PE ratio of 273.10 and a beta of 0.63.

Quintiles Transitional Holdings (NYSE:Q) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.04. The firm had revenue of $1.97 billion during the quarter, compared to the consensus estimate of $1.96 billion. Quintiles Transitional Holdings had a return on equity of 14.23% and a net margin of 0.82%. The business’s revenue for the quarter was up 68.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.93 EPS. On average, analysts predict that Quintiles Transitional Holdings Inc. will post $4.58 earnings per share for the current year.

Quintiles Transitional Holdings announced that its board has authorized a share buyback program on Wednesday, May 24th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 5.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

WARNING: “Quintiles Transitional Holdings Inc. (Q) Director John Connaughton Sells 1,030,429 Shares” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/21/quintiles-transitional-holdings-inc-q-director-john-connaughton-sells-1030429-shares.html.

Several institutional investors and hedge funds have recently bought and sold shares of Q. Fiduciary Trust Co. purchased a new stake in shares of Quintiles Transitional Holdings during the 2nd quarter worth about $105,000. Global X Management Co. LLC raised its stake in shares of Quintiles Transitional Holdings by 30.8% during the 1st quarter. Global X Management Co. LLC now owns 1,469 shares of the medical research company’s stock worth $118,000 after purchasing an additional 346 shares in the last quarter. GWM Advisors LLC purchased a new stake in shares of Quintiles Transitional Holdings during the 2nd quarter worth about $122,000. Korea Investment CORP raised its stake in shares of Quintiles Transitional Holdings by 142.5% during the 2nd quarter. Korea Investment CORP now owns 1,370 shares of the medical research company’s stock worth $123,000 after purchasing an additional 805 shares in the last quarter. Finally, Archford Capital Strategies LLC purchased a new stake in shares of Quintiles Transitional Holdings during the 1st quarter worth about $160,000. 91.34% of the stock is owned by institutional investors.

Several research analysts recently weighed in on the stock. Barclays PLC set a $100.00 target price on shares of Quintiles Transitional Holdings and gave the company a “buy” rating in a research note on Friday, August 4th. Zacks Investment Research downgraded shares of Quintiles Transitional Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Jefferies Group LLC reissued a “hold” rating and issued a $94.00 target price on shares of Quintiles Transitional Holdings in a research note on Friday, August 4th. Stifel Nicolaus reissued a “hold” rating and issued a $92.00 target price (up previously from $87.00) on shares of Quintiles Transitional Holdings in a research note on Friday, August 4th. Finally, William Blair raised shares of Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $70.10 to $93.42 in a research note on Friday, August 4th. Eleven research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $92.44.

About Quintiles Transitional Holdings

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Insider Buying and Selling by Quarter for Quintiles Transitional Holdings (NYSE:Q)

Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.